ECSP22003596A - Moduladores del receptor de nmda - Google Patents

Moduladores del receptor de nmda

Info

Publication number
ECSP22003596A
ECSP22003596A ECSENADI20223596A ECDI202203596A ECSP22003596A EC SP22003596 A ECSP22003596 A EC SP22003596A EC SENADI20223596 A ECSENADI20223596 A EC SENADI20223596A EC DI202203596 A ECDI202203596 A EC DI202203596A EC SP22003596 A ECSP22003596 A EC SP22003596A
Authority
EC
Ecuador
Prior art keywords
nmda receptor
receptor modulators
compounds
depression
disorders
Prior art date
Application number
ECSENADI20223596A
Other languages
English (en)
Inventor
John Kilburn
Mauro Marigo
Laurent David
Erhad Ascic
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of ECSP22003596A publication Critical patent/ECSP22003596A/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B62—LAND VEHICLES FOR TRAVELLING OTHERWISE THAN ON RAILS
    • B62D—MOTOR VEHICLES; TRAILERS
    • B62D15/00—Steering not otherwise provided for
    • B62D15/02—Steering position indicators ; Steering position determination; Steering aids
    • B62D15/027—Parking aids, e.g. instruction means
    • B62D15/0285—Parking performed automatically
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60W—CONJOINT CONTROL OF VEHICLE SUB-UNITS OF DIFFERENT TYPE OR DIFFERENT FUNCTION; CONTROL SYSTEMS SPECIALLY ADAPTED FOR HYBRID VEHICLES; ROAD VEHICLE DRIVE CONTROL SYSTEMS FOR PURPOSES NOT RELATED TO THE CONTROL OF A PARTICULAR SUB-UNIT
    • B60W30/00—Purposes of road vehicle drive control systems not related to the control of a particular sub-unit, e.g. of systems using conjoint control of vehicle sub-units
    • B60W30/06—Automatic manoeuvring for parking
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60W—CONJOINT CONTROL OF VEHICLE SUB-UNITS OF DIFFERENT TYPE OR DIFFERENT FUNCTION; CONTROL SYSTEMS SPECIALLY ADAPTED FOR HYBRID VEHICLES; ROAD VEHICLE DRIVE CONTROL SYSTEMS FOR PURPOSES NOT RELATED TO THE CONTROL OF A PARTICULAR SUB-UNIT
    • B60W60/00—Drive control systems specially adapted for autonomous road vehicles
    • B60W60/001—Planning or execution of driving tasks
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60W—CONJOINT CONTROL OF VEHICLE SUB-UNITS OF DIFFERENT TYPE OR DIFFERENT FUNCTION; CONTROL SYSTEMS SPECIALLY ADAPTED FOR HYBRID VEHICLES; ROAD VEHICLE DRIVE CONTROL SYSTEMS FOR PURPOSES NOT RELATED TO THE CONTROL OF A PARTICULAR SUB-UNIT
    • B60W2510/00—Input parameters relating to a particular sub-units
    • B60W2510/20—Steering systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Transportation (AREA)
  • Mechanical Engineering (AREA)
  • Automation & Control Theory (AREA)
  • Epidemiology (AREA)
  • Combustion & Propulsion (AREA)
  • Human Computer Interaction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a nuevos moduladores del receptor de NMDA. Aspectos separados de las invenciones se refieren a composiciones farmacéuticas que comprenden dichos compuestos y a usos de los compuestos para tratar trastornos neurológicos o trastornos neuropsiquiátricos tales como la depresión.
ECSENADI20223596A 2019-07-03 2022-01-17 Moduladores del receptor de nmda ECSP22003596A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201900821 2019-07-03

Publications (1)

Publication Number Publication Date
ECSP22003596A true ECSP22003596A (es) 2022-02-25

Family

ID=74065626

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20223596A ECSP22003596A (es) 2019-07-03 2022-01-17 Moduladores del receptor de nmda

Country Status (21)

Country Link
US (1) US11466027B2 (es)
EP (1) EP3994141A1 (es)
JP (1) JP2022539197A (es)
KR (1) KR20220029568A (es)
CN (1) CN114008054A (es)
AR (1) AR119340A1 (es)
AU (1) AU2020299992A1 (es)
BR (1) BR112021003928A2 (es)
CA (1) CA3144304A1 (es)
CL (1) CL2021003557A1 (es)
CO (1) CO2021017142A2 (es)
CR (1) CR20210662A (es)
EC (1) ECSP22003596A (es)
IL (1) IL289575A (es)
JO (1) JOP20210331A1 (es)
MA (1) MA56451A (es)
MX (1) MX2021015742A (es)
PE (1) PE20220137A1 (es)
PH (1) PH12021553286A1 (es)
TW (1) TW202116779A (es)
WO (1) WO2021001423A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021000297A1 (en) 2019-07-03 2021-01-07 Merck Sharp & Dohme Corp. Compounds and methods of use thereof as antibacterial agents
US11358971B2 (en) 2019-07-03 2022-06-14 H. Lundbeck A/S Prodrugs of modulators of the NMDA receptor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026700A (en) 1989-05-16 1991-06-25 Merrell Dow Pharmaceuticals Certain quinolines and thienopyridines as excitatory amino acid antagonists
US5252581A (en) 1992-07-20 1993-10-12 Hoechst-Roussel Pharmaceuticals Inc. Substituted aminothienopyridines, pharmaceutical composition and use
US6071970A (en) 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
PT743853E (pt) 1994-02-08 2001-10-31 Nps Pharma Inc Compostos activos num novo local em canis de calcio activados por um receptor uteis para o tratamento de perturbacoes e doencas neurologicas
JP2002511835A (ja) 1996-06-07 2002-04-16 エヌピーエス・ファーマシウティカルズ・インコーポレイテッド 神経障害および神経病の治療に有用な受容体作動性カルシウムチャネル上の新規部位で活性な化合物
WO1998056752A1 (en) 1997-06-11 1998-12-17 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
KR20130044381A (ko) * 2010-03-04 2013-05-02 머크 샤프 앤드 돔 코포레이션 카테콜 ｏ－메틸 트랜스퍼라제의 억제제 및 정신병적 장애의 치료에서의 그의 용도
US11358971B2 (en) 2019-07-03 2022-06-14 H. Lundbeck A/S Prodrugs of modulators of the NMDA receptor

Also Published As

Publication number Publication date
WO2021001423A1 (en) 2021-01-07
PE20220137A1 (es) 2022-01-27
CL2021003557A1 (es) 2022-08-19
AR119340A1 (es) 2021-12-09
CA3144304A1 (en) 2021-01-07
US11466027B2 (en) 2022-10-11
CR20210662A (es) 2022-03-02
EP3994141A1 (en) 2022-05-11
CN114008054A (zh) 2022-02-01
PH12021553286A1 (en) 2022-08-01
IL289575A (en) 2022-03-01
CO2021017142A2 (es) 2022-01-17
US20210002292A1 (en) 2021-01-07
MA56451A (fr) 2022-05-11
AU2020299992A1 (en) 2022-02-24
MX2021015742A (es) 2022-01-27
JOP20210331A1 (ar) 2023-01-30
JP2022539197A (ja) 2022-09-07
TW202116779A (zh) 2021-05-01
BR112021003928A2 (pt) 2021-05-18
KR20220029568A (ko) 2022-03-08

Similar Documents

Publication Publication Date Title
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
SV2016005311A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
MX2013012896A (es) Compuestos novedosos como moduladores de proteina cinasas.
CL2018003265A1 (es) Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
DOP2018000204A (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
UY36126A (es) ?compuestos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol sustituidos como agentes de direccionamiento al asgpr?.
CL2015002121A1 (es) Modulares de receptores nmda de espiro-lactama y sus usos.
CL2021003534A1 (es) Profármacos de moduladores del receptor de nmda.
DOP2017000117A (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
MX2019000980A (es) Compuestos y composiciones y usos de los mismos.
MX373946B (es) Reguladores a la baja del receptor de estrogeno selectivo de benzotiofeno.
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
MX2018002446A (es) Compuestos heterociclicos fusionados como moduladores s1p.
MX2018014114A (es) Derivados del sobetiroma.
MX2021011008A (es) Compuestos piperidinil biciclicos fusionados y relacionados como modulares del receptor c5a.
ECSP22003596A (es) Moduladores del receptor de nmda
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
MX2019000982A (es) Compuestos y composiciones y usos de los mismos.
DOP2022000026A (es) Derivados de alcohol como abridores del canal de potasio kv7
MX2020002196A (es) Moduladores receptores de tipo a de ácido gammaaminobutírico novedosos para trastornos del humor.